The Parties intend to negotiate a strategic partnership to support U.S. Good Manufacturing Practice (“GMP”) manufacturing, clinical supply, and potential commercialization of bone marrow–derived mesenchymal stem cell (“MSC”) exosomes in the U.S. and international markets. The collaboration is expected to combine Exo-Top’s MSC Master Cell Bank (“MCB”) and exosome production

NurExone competed in the Healthcare category at the BOLD Awards VII, standing out among seven other leading companies in the field. The selection was made by a panel of judges composed of global market leaders, innovators, and change-makers. The principal judge for the Healthcare category was Mr. Ben Beckley, CEO of RevHealth. Ben

The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer

Toronto, Ontario and Haifa, Israel–(Newsfile Corp. – February 10, 2026) – NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion – Israel

TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has

TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome

TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of

TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the third quarter ended September 30, 2025 (“Q3 2025”)

NEW YORK, Nov. 18, 2025 /PRNewswire/ — The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the inaugural 2025 Prix Galien Bridges Awards nominees for “Best Bridge-Builder Institution,” “Best Biomedical Product,” “Best Medical Technology/AI Advances in Human Health,” “Best Product for Rare/Orphan Diseases,” and “Best Public